EUCTR2010-019238-29-NL进行中（未招募）1 期
Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS and NRAS colorectal cancer
European Organisation for Research and Treatment of Cancer0 个研究点目标入组 44 人开始时间: 2013年1月22日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •-Histologically proven CRC with 1 to 8 metachronous or synchronous liver metastases considered to be completely resectable.
- •-Primary tumor (or liver metastasis) of CRC must be KRAS and NRAS status wild type”.
- •-Patients must have undergone complete resection (R0) of the primary tumor at least 4 weeks before randomization. Or for patients with synchronous metastases the primary tumor can be resected (R0) at the same time as the liver metastases if: the patient has a non-obstructive primary tumor and is able to receive preoperative chemotherapy (3-4 months) before surgery.
- •-Measurable hepatic disease by RECIST version 1.1.
- •-Patients must be 18 years old or older.
- •-A WHO performance status of 0 or 1. Radiotherapy alone is allowed if given pre or post protocol treatment.
- •-Previous adjuvant chemotherapy for primary CRC is allowed if completed at least 12 months before inclusion in this study.
- •-Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 14 days prior to the first dose of study treatment.
- •-Patients of childbearing / reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 6 months after the last study treatment. A highly effective method of birth control is defined as those which result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- •-Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
- •-Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 240
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 120
排除标准
- •-No previous chemotherapy for metastatic disease or surgical treatment (e.g. surgical resection or radiofrequency ablation) for liver metastasis.
- •-No evidence of extra-hepatic metastasis (of CRC).
- •-No previous exposure to EGFR or VEGF/VEGFR targeting therapy within the last 12 months.
- •-No major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to randomization.
- •-No regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs). No bleeding diathesis (e.g. hemoptysis of = 1/2 teaspoon or 2.5mL), coagulopathy, or need for administration of full-dose anti-coagulant(s).
- •-Presence of peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events, v4.0) serious wound complications, ulcers, or bone fractures.
- •-Clinically significant cardiovascular disease, including: uncontrolled hypertension, New York Heart Association (NYHA) class II-IV heart failure, myocardial infarction or unstable angina pectoris, cerebrovascular accident or transient ischemic attack within the past 12 months, peripheral vascular disease = grade 2, serious cardiac arrhythmia requiring medication and other clinically significant cardiovascular disease.
- •-Presence of symptomatic diverticulitis or active or uncontrolled gastroduodenal ulceration.
- •-History or evidence of interstitial lung disease (e.g. pneumonitis, pulmonary fibrosis).
- •-Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial.
- •-Significant disease that, in the investigator’s opinion, would exclude the patient from the study. Including known allergy or any other adverse reaction to any of the study drugs (including any of the excipients) or to any related compound, including hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant human or humanized antibodies.
- •-Participation in another clinical study (except sub studies of this protocol) within the 30 days before randomization and during this study.
研究者
相似试验
进行中（未招募）
1 期
Randomized phase II trial evaluating the efficacy of FOLFOX alone, FOLFOX plus bevacizumab and FOLFOX plus panitumumab as perioperative treatment in patients with resectable liver metastases from wild type KRAS and NRAS colorectal cancerEUCTR2010-019238-29-BEEuropean Organisation for Research and Treatment of Cancer44
尚未招募
2 期
A clinical trial to study the efficacy of intravenous albumin infusion along with corticosteroids and nutrition in patients with Acute Severe Ulcerative ColitisCTRI/2020/12/029656AIIMS
尚未招募
Unknown
Modif-i Tobacco Trial: A clinical trial of the efficacy of a brain-training” smartphone app to assist tobacco cessatioTobacco Use DisorderMental Health - AddictionACTRN12624000633583Eastern Health200
已完成
不适用
Efficacy of cognitive behavioural therapy and/or simulation-based learning resources on the mental health of chronic obstructive pulmonary disease patients.AnxietyChronic obstructive pulmonary diseaseRespiratory - Chronic obstructive pulmonary diseaseMental Health - AnxietyMental Health - DepressionDepressionACTRN12616001039471Edith Cowan University192
已完成
不适用
Milrinone treatment versus conventional standard management for children with enterovirus 71-induced pulmonary oedema and/or neurogenic shockISRCTN76926623ational Health Research Institutes (NHRI) (Taiwan)